PAVmed Inc (PAVM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $13.03M
Last updated: Nov 17, 2026 at 11:05 AM ET
PAVmed Inc (PAVM) Earnings: Report Dates and Results
PAVmed (PAVM) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, PAVmed reported EPS of -$0.33, above the -$1.02 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PAVM has an expected report date of Mar 29, 2027.
PAVM Earnings Call
The latest PAVM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, PAVM beat 24, missed 11 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $41000, up 720.0% from $5000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.33 | -$1.02 | N/A | +67.65% | Beat | N/A | 1 | 0 up, 1 down | Nov 13, 2026 | $41000 |
| Jun 30, 2026 | -$0.42 | -$0.66 | N/A | +36.36% | Beat | N/A | 1 | 1 up, 0 down | Aug 14, 2026 | $33000 |
| Mar 31, 2026 | -$1.17 | -$0.69 | -$0.69 - -$0.69 | -69.57% | Miss | N/A | 1 | 1 up, 0 down | May 15, 2026 | $22000 |
| Dec 31, 2025 | -$1.05 | -$4.50 | -$4.50 - -$4.50 | +76.67% | Beat | N/A | 1 | 1 up, 0 down | Mar 26, 2026 | $52000 |
| Sep 30, 2025 | -$0.60 | -$6.00 | N/A | +90.00% | Beat | N/A | 1 | 1 up, 0 down | Nov 13, 2025 | $5000 |
| Jun 30, 2025 | -$1.50 | -$7.50 | N/A | +80.00% | Beat | N/A | 1 | 1 up, 0 down | Aug 14, 2025 | $6000 |
| Mar 31, 2025 | -$0.14 | -$0.31 | N/A | +54.84% | Beat | N/A | 1 | 1 up, 0 down | May 15, 2025 | $8000 |
| Dec 31, 2024 | -$0.19 | -$0.40 | -$0.40 - -$0.40 | +52.50% | Beat | N/A | 1 | 1 up, 0 down | Mar 25, 2025 | $10000 |
| Sep 30, 2024 | -$16.20 | -$39.00 | N/A | +58.46% | Beat | N/A | 1 | 1 up, 0 down | Nov 13, 2024 | $996000 |
| Jun 30, 2024 | -$6.00 | -$40.20 | -$46.85 - -$39.04 | +85.07% | Beat | N/A | 3 | 0 up, 0 down | Aug 13, 2024 | $979000 |
| Mar 31, 2024 | -$2.62 | -$1.67 | -$1.82 - -$1.48 | -56.89% | Miss | N/A | 3 | 1 up, 0 down | May 13, 2024 | $1.01M |
| Dec 31, 2023 | -$46.92 | -$53.70 | -$63.06 - -$44.14 | +12.63% | Beat | N/A | 3 | 0 up, 0 down | Mar 26, 2024 | $1.05M |
| Sep 30, 2023 | -$37.45 | -$63.00 | -$67.53 - -$54.03 | +40.56% | Beat | N/A | 3 | 0 up, 0 down | Nov 14, 2023 | $791000 |
| Jun 30, 2023 | -$46.41 | -$69.75 | N/A | +33.46% | Beat | N/A | 2 | 0 up, 0 down | Aug 15, 2023 | $166000 |
| Mar 31, 2023 | -$54.86 | -$74.25 | N/A | +26.11% | Beat | N/A | 3 | 0 up, 0 down | May 16, 2023 | $446000 |
| Dec 31, 2022 | -$0.23 | -$0.25 | -$0.26 - -$0.23 | +8.00% | Beat | N/A | 3 | 0 up, 0 down | Mar 14, 2023 | $112000 |
| Sep 30, 2022 | -$67.50 | -$105.75 | N/A | +36.17% | Beat | N/A | 2 | 0 up, 0 down | Nov 15, 2022 | $76000 |
| Jun 30, 2022 | -$76.50 | -$90.00 | N/A | +15.00% | Beat | N/A | N/A | 0 up, 0 down | Aug 16, 2022 | N/A |
| Mar 31, 2022 | -$63.00 | -$85.50 | -$94.55 - -$76.54 | +26.32% | Beat | N/A | 4 | 1 up, 0 down | May 12, 2022 | $189000 |
| Dec 31, 2021 | -$0.20 | -$0.15 | -$0.16 - -$0.14 | -33.33% | Miss | N/A | 2 | 0 up, 0 down | Mar 29, 2022 | $300000 |
| Sep 30, 2021 | -$45.00 | -$42.75 | N/A | -5.26% | Miss | N/A | 4 | 0 up, 0 down | Nov 22, 2021 | $200000 |
| Jun 30, 2021 | -$36.00 | -$40.50 | N/A | +11.11% | Beat | N/A | 4 | N/A | Aug 12, 2021 | N/A |
| Mar 31, 2021 | -$36.00 | -$40.50 | N/A | +11.11% | Beat | N/A | 2 | N/A | May 17, 2021 | N/A |
| Dec 31, 2020 | -$0.17 | -$0.11 | -$0.12 - -$0.11 | -54.55% | Miss | N/A | 2 | N/A | Feb 22, 2021 | N/A |
| Sep 30, 2020 | -$45.00 | -$49.50 | -$49.52 - -$45.02 | +9.09% | Beat | N/A | 2 | N/A | Nov 17, 2020 | N/A |
| Jun 30, 2020 | -$58.50 | -$49.50 | N/A | -18.18% | Miss | N/A | N/A | N/A | Aug 18, 2020 | N/A |
| Mar 31, 2020 | -$148.50 | -$49.50 | N/A | -200.00% | Miss | N/A | 1 | N/A | Apr 9, 2020 | N/A |
| Dec 31, 2019 | -$0.19 | -$0.11 | -$0.11 - -$0.11 | -72.73% | Miss | N/A | 1 | N/A | Dec 31, 2019 | N/A |
| Sep 30, 2019 | -$45.00 | -$45.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 21, 2019 | N/A |
| Jun 30, 2019 | -$58.50 | -$58.50 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 14, 2019 | N/A |
| Mar 31, 2019 | -$58.50 | -$58.50 | N/A | 0.00% | In line | -292600.0% | 1 | N/A | Apr 4, 2019 | N/A |
| Dec 31, 2018 | -$0.15 | -$0.14 | N/A | -7.14% | Miss | N/A | N/A | N/A | Mar 31, 2019 | N/A |
| Sep 30, 2018 | -$37.44 | -$54.00 | N/A | +30.67% | Beat | N/A | N/A | N/A | Nov 15, 2018 | N/A |
| Jun 30, 2018 | -$54.86 | -$49.50 | N/A | -10.83% | Miss | N/A | N/A | N/A | Aug 14, 2018 | N/A |
| Mar 31, 2018 | $0.02 | $0.02 | N/A | 0.00% | In line | N/A | N/A | N/A | May 21, 2018 | N/A |
| Sep 30, 2017 | -$86.76 | -$63.00 | N/A | -37.71% | Miss | N/A | N/A | N/A | Nov 15, 2017 | N/A |
| Jun 30, 2017 | -$36.00 | -$63.00 | N/A | +42.86% | Beat | N/A | N/A | N/A | Aug 14, 2017 | N/A |
| Mar 31, 2017 | -$63.00 | -$63.00 | N/A | 0.00% | In line | N/A | N/A | N/A | May 22, 2017 | N/A |
| Dec 31, 2016 | -$58.50 | -$63.00 | N/A | +7.14% | Beat | N/A | N/A | N/A | Feb 16, 2017 | N/A |
| Sep 30, 2016 | -$63.00 | -$67.50 | N/A | +6.67% | Beat | N/A | N/A | N/A | Nov 10, 2016 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.29, after -$25.01 the year before. It was -$121.60 for the year ended Dec 31, 2016, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.29 | N/A |
| Dec 31, 2024 | -$25.01 | N/A |
| Dec 31, 2023 | -$185.64 | N/A |
| Dec 31, 2022 | -$207.23 | N/A |
| Dec 31, 2021 | -$117.20 | N/A |
| Dec 31, 2020 | -$252.17 | N/A |
| Dec 31, 2019 | -$162.19 | N/A |
| Dec 31, 2018 | -$278.19 | N/A |
| Dec 31, 2016 | -$121.60 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,100 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,084 | 6 | |
| 2026Q2 | Jun 30, 2026 | 3,096 | 6 | |
| 2026Q1 | Mar 31, 2026 | 3,543 | 6 | |
| 2025Q4 | Dec 31, 2025 | 5,261 | 6 | |
| 2025Q3 | Sep 30, 2025 | 4,931 | 5 | |
| 2025Q1 | Mar 31, 2025 | 3,093 | 6 | |
| 2024Q3 | Sep 30, 2024 | 3,324 | 7 | |
| 2024Q2 | Jun 30, 2024 | 3,751 | 7 |
2026Q3 Earnings Call
Opening remarks
Matthew Riley Vice President, Investor Relations Thank you, operator, and good morning, everyone. Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog, Chairman and Chief Executive Officer of PAVmed, along with Dennis McGrath, Chief Financial Officer of PAVmed. The press release announcing our business update and financial results is available on PAVmed's website. Please take a moment to read the disclaimers about forward-looking statements in the press release. The business update press release and conference call include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings with the SEC. For a list and description of these and other important risks and uncertainties that may affect future operations, see Part I, Item 1A, entitled “Risk Factors,” in PAVmed's most recent annual report on Form 10-K filed with the SEC, and any subsequent updates filed in quarterly reports on Forms 10-Q and subsequent Forms 8-K. Except as required by law, PAVmed disclaims any intentions or obligations to publicly update or revise any forward-looking statements to reflect changes in expectations or in events, conditions, or circumstances on which the expectations may be based or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. I would now like to turn the call over to Dr. Lishan Aklog, Chairman and CEO of PAVmed.
Lishan Aklog Chairman and CEO Thank you, Matt, and good morning, everyone. Thank you for joining our quarterly update call. We're very encouraged by developments across our PAVmed portfolio. The most important development, of course, is that Lucid has secured Medicare reimbursement for EsoGuard, and this is a critical and transformational milestone. On the other front, Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are now actively engaged with the FDA on our two other portfolio units, PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value. Let me start with Lucid. The most significant development at Lucid is that Medicare is now reimbursing EsoGuard. Lucid began submitting claims through its Texas laboratory in late September and has been paid consistently since October at the full Medicare rate. The engagement with the contractor and subsequent consistent pattern constitutes Medicare coverage through claim-by-claim adjudication, and this applies to Medicare patients nationwide. With Medicare reimbursement now secured, Lucid immediately and aggressively transitioned its commercial activity to focus on access to EsoGuard in the Medicare population.
Frequently Asked Questions About PAVM
When is PAVmed's next earnings date?
PAVmed's next earnings report is expected for Mar 29, 2027.
Did PAVM beat earnings estimates last quarter?
Yes. PAVmed reported EPS of -$0.33 for the quarter ended Sep 30, 2026, above the -$1.02 estimate, a 67.65% surprise.
What EPS do analysts expect from PAVM next quarter?
The consensus EPS estimate for PAVmed for the quarter ending Dec 31, 2026 is -$0.57 from 4 analysts.
How often does PAVM beat earnings estimates?
PAVmed beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +48.56%.
PAVM pages: Overview, Earnings, Forecast, Financials, Competitors